Opinion|Videos|November 19, 2025
Improving Care for mCRC: Overcoming Barriers and Building Confidence in Community Practice
Panelists discuss how addressing barriers and sharing real-world data can increase community confidence in prescribing third-line metastatic colorectal therapies.
Advertisement
Episodes in this series
Panelists highlight barriers in community practice that limit third-line therapy uptake, including lack of familiarity with new agents and limited access to data.
They discuss strategies such as sharing real-world safety and patient-reported outcomes data, educational initiatives, and peer-to-peer engagement to build clinician confidence.
Improving data dissemination and support structures can help ensure more patients receive evidence-based therapies outside academic centers.
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5